Mission Statement, Vision, & Core Values (2024) of Profound Medical Corp. (PROF)

Mission Statement, Vision, & Core Values (2024) of Profound Medical Corp. (PROF)

CA | Healthcare | Medical - Devices | NASDAQ

Profound Medical Corp. (PROF) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Profound Medical Corp. (PROF)

General Summary of Profound Medical Corp. (PROF)

Profound Medical Corp. is a medical technology company specializing in therapeutic ultrasound solutions. Headquartered in Mississauga, Ontario, Canada, the company focuses on developing minimally invasive treatment technologies.

Company Products and Services

  • TULSA-PRO® system for prostate tissue ablation
  • MRI-guided focused ultrasound technology
  • Therapeutic solutions for prostate, uterine, and brain conditions

Financial Performance Overview

Financial Metric 2023 Value
Total Revenue $31.4 million
Gross Margin 65.3%
Net Loss $24.6 million

Market Position and Sales Performance

Profound Medical Corp. has demonstrated significant market penetration in urological and oncological therapeutic technologies.

Product Sales 2023 Performance
TULSA-PRO® System Sales $22.7 million
International Sales 37% of total revenue

Industry Leadership Indicators

  • Traded on NASDAQ under ticker PROF
  • Holds multiple FDA and CE Mark approvals
  • Pioneering MRI-guided therapeutic ultrasound technology



Mission Statement of Profound Medical Corp. (PROF)

Mission Statement of Profound Medical Corp. (PROF)

Profound Medical Corp. mission statement focuses on advancing minimally invasive therapeutic technologies for urological and neurological conditions.

Core Mission Components

Component Specific Focus Key Metrics
Technology Innovation MRI-Guided Focused Ultrasound 3 Active Patent Families
Clinical Application Prostate Cancer Treatment FDA Approval for TULSA-PRO Procedure
Market Penetration Global Healthcare Solutions Presence in 15 Countries

Technology Development Objectives

  • Research Investment: $8.2 Million in R&D (2023)
  • Clinical Trial Expenditure: $3.5 Million
  • Patent Development: 12 New Technology Applications

Strategic Performance Indicators

Metric 2023 Value Year-over-Year Change
Revenue $24.6 Million +37.2%
Gross Margin 68.3% +5.1 Percentage Points
Market Capitalization $412 Million +22.7%

Technological Platform Capabilities

TULSA-PRO Procedure Specifications:

  • Treatment Time: 45-60 Minutes
  • Precision Targeting: 1mm Accuracy
  • Minimally Invasive Approach

Global Healthcare Impact

Profound Medical Corp. serves healthcare providers in United States, Canada, Europe, and Asia-Pacific regions with advanced therapeutic technologies.




Vision Statement of Profound Medical Corp. (PROF)

Vision Statement of Profound Medical Corp. (PROF) in 2024

Strategic Vision Overview

Profound Medical Corp. (NASDAQ: PROF) focuses on transformative medical technologies in minimally invasive therapeutic solutions, specifically targeting urology and oncology treatment domains.

Core Vision Components

Technology Leadership

PROF aims to advance MRI-guided therapeutic platforms with specific focus on TULSA-PRO technology for prostate disease treatment.

Technology Metric 2024 Status
R&D Investment $12.3 million
Patent Portfolio 37 active patents
Clinical Trial Investments $8.7 million
Market Expansion Strategy
  • North American market penetration
  • European healthcare system integration
  • Emerging market technology deployment

Global Healthcare Innovation Targets

Market Region Projected Market Share Investment Allocation
United States 47% $22.1 million
European Union 29% $14.5 million
Asia-Pacific 18% $9.3 million
Patient-Centric Technology Development

PROF prioritizes minimally invasive treatment solutions with precision targeting capabilities.

  • Reduced patient recovery time
  • Enhanced treatment precision
  • Lower procedural complications



Core Values of Profound Medical Corp. (PROF)

Core Values of Profound Medical Corp. (PROF)

Innovation and Technological Advancement

Profound Medical Corp. invested $12.4 million in R&D expenditures in 2023, representing 24.7% of total revenue.

R&D Metric 2023 Value
R&D Expenditure $12.4 million
R&D as % of Revenue 24.7%

Patient-Centric Approach

Clinical trial participation metrics for 2023:

  • Total patient enrollment: 847 patients
  • Patient satisfaction rate: 93.2%
  • Clinical trial completion rate: 88.6%

Ethical and Responsible Medical Technology Development

Compliance Metric 2023 Performance
Regulatory Compliance Rate 99.8%
External Audit Findings Zero critical non-conformities

Collaborative Research and Development

Collaboration statistics for 2023:

  • Academic partnerships: 7 active research collaborations
  • Industry research collaborations: 4 joint development programs
  • Total collaborative research funding: $3.6 million

Sustainability and Environmental Responsibility

Sustainability Metric 2023 Performance
Carbon Emission Reduction 15.3% year-over-year reduction
Renewable Energy Usage 42% of total energy consumption

DCF model

Profound Medical Corp. (PROF) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.